Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Chemo + Warfarin in Androgen-Independent Prostate Cancer
NCT00014352Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2000
- Primary completion
- Mar 2003
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, estramustine, doxorubicin and ketoconazole in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Safety and toxicity, Efficacy and 2 more. Started Sep 2000; status: completed.
02
Drugs
docetaxelestramustinedoxorubicinketoconazole
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00014352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014352.